- Marijuana stocks have suffered on Tuesday after a warning from the FDA.
- Other headwinds may be starting to fade for Aurora Cannabis (ACB).
- Canopy's Canadian license may help it recover as well.
- Tilray's (TLRY) low price may help it recover from the lows.
The US Food and Drug Administration (FDA) has been weighing on cannabis stocks with fresh guidance. The might regulator has said that CBD products may cause liver injury and other damages. The news came as another blow to the marijuana sector which has been struggling with a slow Candian blowout and financial issues.
Prices of pot stocks declined across the board, extending their climbdown after rising last week on hopes for US legalization.
However, some positive news may help individual stocks.
Aurora Cannabis (ACB) Stock Price
Aurora has neared the recent cycle lows of $3 per share but may find buyers after announcing a new deal. The Edmonton-based company will develop CBD topicals with UFC and is set open a flagship WEM store, which will be Canada's largest retail space for marijuana products.
ACB's stock price may rise after it will save some C$190 by abandoning the construction of two facilities. The news comes after the company concluded its convertible debentures swap.
Overall, the firm may enjoy a better financial footing.
Canopy Growth Corp (CGC) Stock Price
Canopy Growth Corporation (CGC) has managed to weather the storm may be ready for a recovery. The firm invested in hemp assets in the state of New York. Moreover, CGC has a massive war chest of funds that could help it survive in case of a downturn, while its competitors are weeded out.
The Smiths Falls, Ontario based firm has also enjoyed an upgrade from Bank of America, which may convince institutional investors to jump in.
Tilray (TLRY) Stock Price
Tilray Inc. based in Nanaimo, on Vancouver Island, was one of the darlings of the stock markets in 2018, when interest in marijuana stocks went sky-high. After a peak near $150, Tilray's price has been declining.
Tilray (TLRY) is trading around $20, a massive downfall, but that may be an attractive price. The firm, which has operations in Australia, New Zealand, Portugal, Germany, and also Latin America, may enjoy bargain seekers.
While the company lost some C$47 million, its revenue soared to $68.
Investing in Cannabis Stocks
Since Canada fully legalized marijuana in late 2018, weed shares have been on a roller coaster ride. Similar to the dot-com bubble, the potential is always there, but the hype proved exaggerated.
As the industry matures, investors are crunching companies' finances and health regulators are also stepping in. Many companies that tried to ride the tide may find themselves out of business, while
More Top 3 Cannabis Stocks: Aurora(ACB), Canopy(CGC), New Age(NBEV), high volatility, different directions
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds below 1.0750 ahead of key US data
EUR/USD trades in a tight range below 1.0750 in the European session on Friday. The US Dollar struggles to gather strength ahead of key PCE Price Index data, the Fed's preferred gauge of inflation, and helps the pair hold its ground.
GBP/USD consolidates above 1.2500, eyes on US PCE data
GBP/USD fluctuates at around 1.2500 in the European session on Friday following the three-day rebound. The PCE inflation data for March will be watched closely by market participants later in the day.
Gold clings to modest daily gains at around $2,350
Gold stays in positive territory at around $2,350 after closing in positive territory on Thursday. The benchmark 10-year US Treasury bond yield edges lower ahead of US PCE Price Index data, allowing XAU/USD to stretch higher.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
US core PCE inflation set to signal firm price pressures as markets delay Federal Reserve rate cut bets
The core PCE Price Index, which excludes volatile food and energy prices, is seen as the more influential measure of inflation in terms of Fed positioning. The index is forecast to rise 0.3% on a monthly basis in March, matching February’s increase.